Singapore markets closed

Novo Nordisk A/S (NOVO-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
991.00+11.30 (+1.15%)
At close: 04:59PM CEST
Full screen
Previous close979.70
Open984.70
Bid991.00 x 0
Ask991.00 x 0
Day's range977.00 - 996.90
52-week range504.40 - 997.40
Volume2,148,717
Avg. volume2,503,166
Market cap4.383T
Beta (5Y monthly)0.17
PE ratio (TTM)49.75
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield12.80 (1.29%)
Ex-dividend date22 Mar 2024
1y target estN/A
All
News
  • GlobeNewswire

    Novo Nordisk A/S - share repurchase programme

    Bagsværd, Denmark, 10 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiat

  • PR Newswire

    Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®

    Novo Nordisk today launched The Power of Wegovy®, a new national campaign. The campaign aims to educate on the clinical data of Wegovy® (semaglutide) 2.4 mg injection and reflect the collective empowerment people living with obesity can feel when they don't have to manage their weight alone.

  • GlobeNewswire

    Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

    Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the